24274-48-4

Basic information

• Product Name: 1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-
• Synonyms: 1,3-Benzenediol,2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-, (1R-trans)-;Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-propyl- (8CI); CBD-V; Cannabidivarin;Cannabidivarol
• CAS NO: 24274-48-4
• Molecular Formula: C₁₉H₂₆O₂
• Molecular Weight: 286.4085
• Mol File: 24274-48-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 439.4°C at 760 mmHg
• Flash Point: 199.6°C
• Appearance: /
• Density: 1.046g/cm³
• Vapor Pressure: 2.49E-08mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: -70°C
• PKA: 9.62±0.45(Predicted)
• CAS DataBase Reference: 1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-(24274-48-4)
• EPA Substance Registry System: 1,3-Benzenediol,2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-propyl-(24274-48-4)

Safety Data

• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 1
• Hazardous Substances Data: 24274-48-4(Hazardous Substances Data)

Usage

Physiological activity

Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within?Medical Cannabis. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana?3. Compared to its homolog,?Cannabidiol, CBDV is shortened by two methyl (CH2) groups on its side chain. Notably, both?Cannabidiol?and CBDV have demonstrated anticonvulsant activity in animal and human models and are demonstrating promising clinical trial results.

Effects

Cannabidivarol（CBDV） has anticonvulsant effects.

General Description

Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis that reportedly has therapeutic efficacy in the treatment of pain, mood disorders, and inflammatory diseases. This certified Snap-N-Spike? solution is suitable for cannabidivarin testing methods by GC/MS, LC/MS or HPLC for applications in clinical toxicology, testing of Cannabis potency or impurity profiling, pharmaceutical research, forensic analysis, and urine drug testing. Cerilliant solution Certified Reference Materials (CRMs) of cannabinoids are supplied in a convenient, quantitative, US DEA-exempt solution format and with TK#s for Canadian customers.

InChI:InChI=1/C19H26O2/c1-5-6-14-10-17(20)19(18(21)11-14)16-9-13(4)7-8-15(16)12(2)3/h9-11,15-16,20-21H,2,5-8H2,1,3-4H3/t15-,16+/m1/s1

Upstream product

• 500-49-2 5-propyl-1,3-benzenediol 
• 156567-57-6 propylzinc bromide 
• 927-77-5 n-propylmagnesium bromide 
• 22972-51-6 (1S,4R)-p-mentha-2,8-dien-1-ol 
• 108-73-6 3,5-dihydroxyphenol 
• 861892-40-2 (4R)-1-methyl-4-(2-(1-propylene))-2-cyclohexene-2-ol 
• 21855-51-6 2,4-dihydroxy-6-propylbenzoic acid ethyl ester 
• 21855-48-1 3,5-dibromo-2,4-dihydroxy-6-propylbenzoic acid ethyl ester 

Downstream Products

• 31262-38-1 3-norpentyl-3-propyl-Δ⁸-tetrahydrocannabinol 
• 31262-37-0 tetrahydrocannabivarin 
• 31932-13-5 CBDVA 
• 28172-17-0 (6aS,10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol 

Relevant articles and documents

Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid, from Thai cannabis, Meao Variant

Four new cannabinoids acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid were isolated from Thai Cannabis 'Meao variant' and these structures were elucidated on the basis of chemical and spectral data. This is the first example of the isolation of propyl cannabinoid acid from Cannabis.

Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2Receptor Derived from the Natural Product Cannabidiol

Cannabidiol (CBD), the second most abundant of the active compounds found in the Cannabis sativa plant, is of increasing interest because it is approved for human use and is neither euphorizing nor addictive. Here, we design and synthesize novel compounds taking into account that CBD is both a partial agonist, when it binds to the orthosteric site, and a negative allosteric modulator, when it binds to the allosteric site of the cannabinoid CB2 receptor. Molecular dynamic simulations and site-directed mutagenesis studies have identified the allosteric site near the receptor entrance. This knowledge has permitted to perform structure-guided design of negative and positive allosteric modulators of the CB2 receptor with potential therapeutic utility.

METHODS FOR SYNTHESIS OF CANNABINOID COMPOUNDS

The present invention provides simple synthetic routes for the preparation of cannabinoid compounds such as CBD, CBDV, THC, THCV, CBN, HU-308, CBG, CBC, and derivatives thereof, which are stereoselective and provide the desired cannabinoid compound in high yield.